Related Experiment Video
Updated: Sep 14, 2025
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Trivalent bispecific anti-MSLN2/CD3 antibody for cancer treatment
Jorge Antonio Perez Saldaña1, Donaciano Flores-Robles1, Antonio Celestino Montes1
1Centro de Investigaciones Microbiológicas, Universidad Autónoma de Guerrero, Chilpancingo, México.
Introduction:
Mesothelin protein is an overexpressed molecule in epithelioid mesothelioma, epithelial ovarian cancer, and pancreatic adenocarcinoma, which is why it is considered a potential therapeutic target.
Areas Covered:
WO2024082060 patent describes a trivalent bispecific antibody directed against MSLN/CD3/MSLN, and lung cancer treatment method. This antibody exhibits binding activity to MSLN-containing tumor cells, as well as inhibition of tumor growth rate in murine models of lung and ovarian cancer.
Expert Opinion:
The trispecific structure suggesting that this antibody is a potential candidate for clinical trials for the treatment of lung cancer associated with high levels of MSLN expression.
Insights
A new trivalent bispecific antibody targets mesothelin (MSLN) and CD3, showing promise for treating MSLN-expressing lung cancers. This antibody effectively binds tumor cells and inhibits growth in preclinical models.
Area of Science:
- Oncology
- Immunotherapy
- Protein Engineering
Background:
- Mesothelin (MSLN) is overexpressed in several cancers, including mesothelioma, ovarian, and pancreatic adenocarcinomas.
- This overexpression makes MSLN a significant therapeutic target for various malignancies.
Purpose of the Study:
- To describe a novel trivalent bispecific antibody targeting MSLN and CD3.
- To evaluate the efficacy of this antibody in preclinical cancer models.
Main Methods:
- Development of a trivalent bispecific antibody targeting MSLN and CD3 (MSLN/CD3/MSLN).
- Assessment of antibody binding to MSLN-expressing tumor cells.
- Evaluation of tumor growth inhibition in murine models of lung and ovarian cancer.
Main Results:
- The bispecific antibody demonstrated binding activity to tumor cells expressing MSLN.
- Significant inhibition of tumor growth rate was observed in preclinical lung and ovarian cancer models.
Conclusions:
- The trispecific antibody design shows potential for clinical development.
- This antibody is a promising candidate for treating lung cancer with high MSLN expression.
